Jounce Therapeutics announced the phase 2 EMERGE trial will be discontinued following early evaluation of clinical data. The open label study was designed to evaluate the safety and efficacy of vopratelimab in combination with ipilimumab in adult subjects with advanced and/or refractory non-small cell lung cancer (NSCLC) and urothelial cancer. Early evaluation of the data from the EMERGE trial in PD-(L)1 inhibitor experienced NSCLC patients indicates the trial will not meet pre-specified interim criteria for continuation of enrollment. Therefore, the EMERGE trial will not be expanded to the patients with urothelial cancer.
A separate randomized Phase 2 trial, SELECT, of vopratelimab in combination with Jounce’s PD-1 inhibitor, JTX-4014 began enrollment in October 2020. The trial compares vopratelimab plus JTX-4014 to JTX-4014 alone in immunotherapy naïve NSCLC patients who have been pre-selected with the TISvopra predictive biomarker. SELECT will enroll approximately 75 patients. Preliminary efficacy data from the SELECT trial is expected in 2021.
Vopratelimab is a monoclonal antibody that binds to and activates ICOS, the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in many solid tumors.
Non-Small Cell Lung Cancer
Non-small cell lung cancer is a group of lung cancers that behave similarly, such as squamous cell carcinoma and adenocarcinoma. Symptoms are a cough that won’t go away, shortness of breath, weight loss, or coughing up blood. Treatments include surgery, chemotherapy, and radiation.
About 80% to 85% of lung cancers are NSCLC. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as NSCLC because their treatment and prognoses (outlook) are often similar.